6 completed, 2 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 2 |
Follow danicopan: new trials by email Literature Review of danicopan trials Research Report on danicopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration Danicopan, Placebo - Geographic Atrophy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 365 | 2021-08-23 | 2025-09-05 |
| ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 Danicopan, Placebo, Remdesivir - COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 201 | 2021-08-03 | 2023-06-08 |
| A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 22 | 2018-06-20 | 2023-08-21 |
| A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Danicopan, Placebo - C3 Glomerulopathy, C3 Glomerulonephritis | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2018-06-12 | 2022-10-14 |
| Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab Danicopan, Eculizumab - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 12 | 2018-05-08 | 2023-12-12 |
| A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Danicopan - C3 Glomerulonephritis, Dense Deposit Disease | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 6 | 2017-08-09 | 2021-11-04 |
| A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) ACH-0144471 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 8 | 2017-06-22 | 2023-03-14 |
| Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Danicopan - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 10 | 2017-03-31 | 2022-06-23 |
Glomerulonephritis, Membranoproliferative (3) · Hemoglobinuria, Paroxysmal (3) · Hemoglobinuria (2) · COVID-19 (1) · Geographic Atrophy (1)
Alexion Pharmaceuticals, Inc. (7) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Italy (5) · United States (5) · United Kingdom (4) · Australia (3) · South Korea (3) · Belgium (2) · Netherlands (2) · New Zealand (2) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Japan (1) · Latvia (1) · Slovakia (1)
PMID 36423588, PMID 33121236, PMID 34314483, PMID 37314061, PMID 41124654
2016 (3), 2017 (3)